). Previous studies have demonstrated that multiple signaling pathways in different cell lineages can mediate the phosphorylation and activation of CREB. These include a protein kinase A (PKA)-dependent pathway that is activated by increased intracellular cAMP (2, 3), a calcium/calmodulin-dependent pathway in which CREB can be phosphorylated by CaM kinases II and IV (10), and a Ras-dependent pathway in which the serine/threonine kinase RSK2 is thought to phosphorylate CREB on Ser 133 (11). Recent studies have demonstrated that transcriptionally active CREB is required for the activation of normal murine T cells following engagement of the T cell antigen receptor (12). Resting T cells contain exclusively unphosphorylated and inactive CREB. TCR cross-linking leads to the rapid and transient phosphorylation of CREB on Ser 133 . More important, transgenic mice expressing a dominant-negative unphosphorylatable form of CREB display a profound T cell proliferative defect characterized by G 1 cell cycle arrest, markedly decreased IL-2 production, and defective transcriptional induction of multiple Fos and Jun proteins (12). These results were consistent with other reports that demonstrated that T and B cell activation results in CREB phosphorylation and increased CREB DNA-binding activity (13) (14) (15) , that a CREB-binding site is necessary for the induction of the proliferating cell nuclear antigen gene in response to IL-2 in T cells (16, 17) , and that there is a functionally important CREB-binding site in the c-fos promoter (18 -20).
and its concomitant activation. In the studies described in this report, we have investigated the signaling pathway(s) that are responsible for CREB activation in normal T cells. Using pharmacological agonists, we show that protein kinase C (PKC)-, calcium/calmodulin-, and protein kinase A-dependent pathways are each capable of independently eliciting CREB phosphorylation in T cells and thymocytes. Pharmacological inhibitor studies demonstrated that the PKC-mediated signaling pathway is required for TCR-mediated activation of CREB. In contrast, inhibitors of protein kinase A and calmodulin kinases had no effect on CREB phosphorylation following TCR cross-linking. T cells lacking the p56 lck tyrosine kinase failed to phosphorylate CREB in response to TCR engagement. Overexpression of dominant-negative mutant Ras and Raf-1 proteins in Jurkat T cells abolished TCR-mediated CREB phosphorylation, whereas overexpression of the RSK2 serine/threonine kinase significantly potentiated TCR-mediated CREB phosphorylation. Taken together, these experiments are consistent with a model in which TCR engagement leads to the rapid phosphorylation and activation of CREB via a signaling pathway involving the activation of p56 lck , PKC, Ras, Raf-1, MEK, and RSK2. Given the importance of CREB phosphorylation in normal T cell activation, this pathway may be an attractive target for the development of novel immunosuppressive agents.
CREB
1 is a 43-kDa basic leucine zipper (bZip) transcription factor composed of a C-terminal basic DNA-binding domain, an adjacent leucine zipper dimerization domain, and a kinaseinducible transcriptional activation domain. CREB binds to cAMP-responsive element sequence elements (TGANNTCA) both as a homodimer and as a heterodimer in association with other members of the CREB/ATF family, including ATF-1 and the cAMP-responsive element modulator (CREM) (1) (2) (3) (4) (5) (6) . Phosphorylation of Ser 133 within the kinase-inducible transcriptional activation domain of CREB is required to induce the transcriptional activity of the protein. Phosphorylation of Ser 133 activates CREB, at least in part, by facilitating its binding to the 256-kDa CREB-binding protein. The CREB⅐CREB-binding protein complex can, in turn, interact with and activate the basal transcriptional machinery (8, 9) . Previous studies have demonstrated that multiple signaling pathways in different cell lineages can mediate the phosphorylation and activation of CREB. These include a protein kinase A (PKA)-dependent pathway that is activated by increased intracellular cAMP (2, 3) , a calcium/calmodulin-dependent pathway in which CREB can be phosphorylated by CaM kinases II and IV (10) , and a Ras-dependent pathway in which the serine/threonine kinase RSK2 is thought to phosphorylate CREB on Ser 133 (11) . Recent studies have demonstrated that transcriptionally active CREB is required for the activation of normal murine T cells following engagement of the T cell antigen receptor (12) . Resting T cells contain exclusively unphosphorylated and inactive CREB. TCR cross-linking leads to the rapid and transient phosphorylation of CREB on Ser 133 . More important, transgenic mice expressing a dominant-negative unphosphorylatable form of CREB display a profound T cell proliferative defect characterized by G 1 cell cycle arrest, markedly decreased IL-2 production, and defective transcriptional induction of multiple Fos and Jun proteins (12) . These results were consistent with other reports that demonstrated that T and B cell activation results in CREB phosphorylation and increased CREB DNA-binding activity (13) (14) (15) , that a CREB-binding site is necessary for the induction of the proliferating cell nuclear antigen gene in response to IL-2 in T cells (16, 17) , and that there is a functionally important CREB-binding site in the c-fos promoter (18 -20) .
Despite the importance of CREB phosphorylation in normal T cell activation, the signaling pathways that regulate CREB phosphorylation (and dephosphorylation) following TCR engagement remained unknown. In the studies described in this report, we have used pharmacological agonists and antagonists, mutant T cell lines, and transient transfection approaches to better define the signaling pathways that regulate CREB phosphorylation in thymocytes and T cells. Our results show that although CREB can be independently phosphorylated by at least three distinct signaling pathways in T cells, TCR cross-linking appears to mediate CREB phosphorylation via a signaling pathway involving the activation of p56 lck , protein kinase C, Ras, Raf-1, MEK, and RSK2.
EXPERIMENTAL PROCEDURES
Animals-CD-1 mice were purchased from Charles River Laboratories (Wilmington, MA). Four to eight-week-old animals were used in the studies described in this report. Animals were maintained in the Uni-versity of Chicago laboratory animal barrier facility in micro-isolator cages. All animal experimentation was carried out according to NIH guidelines and was approved by the animal care committee of the University of Chicago.
Cells-The JCAM-1 and JCAM-1/p409 lck cell lines were a generous gift from Dr. David Straus (University of Chicago). Jurkat and JCAM-1 T cells were grown in RPMI 1640 medium supplemented with 10% fetal bovine serum (Life Technologies, Inc.), 1 mM glutamate, 100 g/ml penicillin, and 100 g/ml streptomycin. JCAM-1/p409 lck cells were grown in the presence of G418 (1 mg/ml) and hygromycin (250 g/ml). Murine splenic T cells were purified using a commercially available T cell column (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. The resulting cells were Ͼ90% CD3 ϩ as assessed by flow cytometry. Single cell suspensions of thymocytes and splenic T cells were cultured in Dulbecco's modified Eagle's medium (Life Technologies, Inc.) containing 10% fetal calf serum, 1 mM glutamate, 100 g/ml penicillin, 100 g/ml streptomycin, 0.1 mM nonessential amino acids, and 0.05 mM 2-mercaptoethanol at 37°C. Splenic T cells and thymocytes (4 ϫ 10 6 cells/ml) were activated by treatment with plasticimmobilized anti-CD3 mAb 145.2C11 (16 g/ml), PMA (10 ng/ml), or ionomycin (0.5 g/ml). Jurkat T cells were activated by treatment with plastic-immobilized OKT3 antibody (10 g/ml). Experiments using inhibitors involved preincubation with each inhibitor for 30 min at 37°C prior to activation. The concentrations of inhibitors used were as follows: bisindolylmaleimide I, 12 M; H-7, 10 M; H-8, 10 M; KN-93, 1 M; W-7, 25 M, chelerythrine chloride, 4 M; and PD98059, 50 M.
Transfections-Exponentially growing Jurkat T cells ( 10 7 ) were transiently transfected using a commercially available eletroporator (BioRad; 250 V, 950 microfarads) with 25 g of an expression vector encoding Gal4-CREB either alone or together with eukaryotic expression vectors encoding wild-type RSK2 (pMT2-HARSK2), a catalytically inactive mutant RSK2 (pMT2-HARSK2(KR100)) (a kind gift from Dr. M. E. Greenberg, Harvard Medical School), constitutively active p21 vHaras , a dominant-negative N17Ras, or a dominant-negative Raf-1 (21) containing an ATP-binding site mutation in the catalytic domain. Following electroporation, the cells were cultured for 48 h at 37°C (1 ϫ 10 6 cells/ml), divided into aliquots, and then activated as described above. Activated cell extracts were used for Western blot analyses as described below.
Antibodies and Pharmacological Reagents-Anti-murine CD3 (145.2C11) and anti-human CD3 (OKT3) antibodies were obtained from Pharmingen (San Diego, CA). PMA, ionomycin, forskolin, H-7
, and W-7 (N-6-aminohexyl-5-chloro-1-naphthalenesulfonamide HCl) were purchased from Calbiochem.
Western Blot Analysis-Protein samples corresponding to 2 ϫ 10 6 T cells were lysed in 50 l of sample buffer (25 mM Tris-HCl (pH 6.7), 2% SDS, 10% glycerol, and 0.008% bromphenol blue). Proteins were resolved by SDS-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes as described previously (21, 22) . Phosphorylated CREB was detected using two different anti-phosphopeptide antibodies that have each been shown previously to react specifically and exclusively with the Ser 133 -phosphorylated form of CREB: (i) a rabbit polyclonal IgG antibody, ␣-pCREB (1:3000 dilution; a generous gift from Dr. M. E. Greenberg) (23) , and (ii) a commercially available rabbit polyclonal IgG prepared against a Ser 133 phospho-CREB peptide (amino acids 123-136, KRREILSRRP(pS)YRK; 1:3000 dilution; Upstate Biotechnology, Inc.). Immunoreactivity was detected with horseradish peroxidase-conjugated goat anti-rabbit Ig (1:2500 dilution; Life Technologies, Inc.) using an enhanced chemiluminescence system (Kirkegaard & Perry Laboratories, Inc., Gaithersburg, MD). A rabbit polyclonal antibody that recognizes both phosphorylated and unphosphorylated forms of CREB (␣-CREB; 1:3000 dilution; a generous gift from Dr. M. E. Greenberg) was used to detect the total levels of CREB protein using identical Western blotting conditions. 133 Phosphorylation of CREB in Normal T Cells-To assess changes in CREB phosphorylation in response to different activation signals in T cells, we performed Western blot analyses using two different rabbit polyclonal antibodies that have been shown previously to specifically and exclusively recognize the Ser 133 -phosphorylated form of CREB (␣-pCREB) (23) . In an initial series of experiments, purified murine splenic T cells were stimulated for 1-120 min with immobilized anti-CD3 mAb (␣-CD3), and the resulting cell lysates were subjected to Western blot analysis with the ␣-pCREB antibody. T cell activation following TCR cross-linking by treatment with ␣-CD3 induced the rapid but transient phosphorylation of CREB Ser 133 (Fig. 1A) . Phosphorylation was observed as early as 1-2 min after TCR cross-linking, peaked within 5 min, and declined steadily over the next 2 h. Of note, total levels of CREB protein as assessed by Western blotting with an ␣-CREB antibody were unchanged during ␣-CD3-mediated T cell activation (Fig. 1A) .
RESULTS

Activation-induced Ser
Cross-linking of TCR with ␣-CD3 activates a number of distinct signaling pathways (24, 25) . The activation of phospholipase C␥ and subsequent phosphatidylinositol 4,5-bisphosphate hydrolysis lead to the generation of diacylglycerol and inositol 1,4,5-trisphosphate. Diacylglycerol activates protein kinase C, whereas inositol 1,4,5-trisphosphate leads to elevations of intracellular Ca 2ϩ and subsequent activation of several calmodulin-dependent enzymes including calcineurin and CaM kinases II and IV. In addition, TCR cross-linking is known to activate the Ras signaling pathway (26 -31) . The TCR-mediated activation of T cells can be simulated by treatment with PMA plus the Ca 2ϩ ionophore ionomycin. To determine directly which of these signaling pathways could result in CREB phosphorylation in purified normal T cells, we analyzed the effects of stimulation with PMA, ionomycin, and PMA ϩ ionomycin on CREB phosphorylation. Incubation of purified splenic T cells with PMA and/or ionomycin resulted in the rapid phosphorylation of CREB on Ser 133 (Fig. 1B) . As compared with TCR cross-linking with the ␣-CD3 antibody, both PMA and ionomycin treatment resulted in slightly more rapid and longer lasting phosphorylation of CREB (compare the 1-and 120-min time points in Fig. 1, A and B) . As was the case for ␣-CD3-mediated activation, treatment with either PMA or ionomycin did not significantly change the total levels of CREB in splenic T cells (Fig. 1B) . These results for splenic T cell activation were confirmed in thymocytes in which stimulation with ␣-CD3, PMA, and ionomycin each was shown to be capable of independently inducing CREB phosphorylation on Ser 133 (Ref. 12 and data not shown).
Effects of Protein Kinase Inhibitors on ␣-CD3-induced CREB Phosphorylation in T Cells-The experiments described above suggested that multiple pathways could result in CREB phos- phorylation in T cells. To determine which of these pathways is required for the TCR-mediated phosphorylation of CREB on Ser 133 , we assessed the effects of specific protein kinase inhibitors on CREB phosphorylation following TCR cross-linking with an ␣-CD3 mAb. Bisindolylmaleimide I has been shown to specifically inhibit PKC activity in intact cells (32, 33) . As shown in Fig. 2A , bisindolylmaleimide I profoundly inhibited ␣-CD3-mediated phosphorylation of CREB. The effect of bisindolylmaleimide I appeared to be specific for PKC because, in control experiments, the same dose of bisindolylmaleimide I inhibited PKC-induced CREB phosphorylation induced by treatment with PMA, but had no effect on PKA-mediated CREB phosphorylation induced by treatment with forskolin ( Fig. 2A) . Further evidence for the critical role of PKC in TCR-mediated CREB phosphorylation came from experiments in which two additional PKC inhibitors, H-7 and chelerythrine chloride, were also shown to inhibit ␣-CD3-induced phosphorylation of CREB on Ser 133 (Fig. 2B) . These results were also in accord with a recent study that demonstrated that depletion of PKC activity by prolonged treatment of T cells with PMA abrogated CREB Ser 133 phosphorylation in response to TCR cross-linking (7) .
H-8 is a specific inhibitor of PKA. As shown in Fig. 2C , preincubation of splenic T cells with H-8 had no effect on ␣-CD3-mediated phosphorylation of CREB in splenic T cells. The dose of H-8 and the preincubation conditions used in these experiments were adequate because, in parallel control experiments, an identical dose of H-8 completely inhibited forskolininduced CREB phosphorylation (Fig. 2C) . Thus, we conclude that PKA is not required for CREB phosphorylation following TCR engagement.
KN-93 and W-7 have been shown previously to inhibit calciumdependent CaM kinase II and calmodulin, respectively, in T cells (34, 35) . As shown in Fig. 2D , W-7 completely inhibited CREB phosphorylation following treatment of purified splenic T cells with ionomycin. On the other hand, KN-93 only partially inhibited CREB phosphorylation following ionomycin treatment (Fig. 2D) . These results were consistent with previous studies that have shown that both CaM kinases II and IV can phosphorylate CREB on Ser 133 (36 -38) . W-7, by inhibiting both enzymes completely, blocked ionomycin-induced CREB phosphorylation, whereas KN-93, which inhibits only CaM kinase II, still allowed partial CREB phosphorylation by CaM kinase IV. In marked contrast to their effects on ionomycinmediated CREB phosphorylation, neither KN-93 nor W-7 significantly inhibited CREB phosphorylation following TCR cross-linking with ␣-CD3 mAb (Fig. 2D) CREB phosphorylation in response to TCR cross-linking, we compared the effects of specific protein kinase inhibitors on TCR-mediated CREB phosphorylation in these two cell types. As was the case in peripheral T cells, both bisindolylmaleimide I and chelerythrine chloride, but not H-8 or W-7, inhibited ␣-CD3-induced CREB phosphorylation on Ser 133 in thymocytes (Fig. 3) . Moreover, ionomycin-induced CREB phosphorylation in thymocytes was also completely inhibited by the calmodulin antagonist, W-7, and partially inhibited by the CaM kinase II inhibitor, KN-93. Thus, in both thymocytes and mature peripheral T cells, PKC-dependent pathways appear to be required for CREB phosphorylation following TCR cross-linking.
TCR-induced Phosphorylation of CREB Requires the Proteintyrosine Kinase p56
lck -Although studies of normal peripheral T cells and thymocytes provide the most accurate assessment of the role of specific signaling pathways in T cell activation, these cells are difficult to transfect and to genetically manipulate.
Thus, it would be useful to identify an immortalized T cell line in which CREB phosphorylation could be induced by TCR cross-linking. Recent studies have demonstrated that stimulation of Jurkat T cells with the ␣-CD3 mAb OKT3 results in the phosphorylation of CREB specifically and exclusively on Ser 133 (7) . We have confirmed these findings and have shown that treatment of Jurkat cells with ␣-CD3 mAb, PMA, or ionomycin induces CREB phosphorylation on Ser 133 (Fig. 4, A and B) . Thus, wild-type and mutant Jurkat cells represent a useful model system for studying CREB phosphorylation in a cultured cell line. p56 lck , a T cell-restricted member of the Src family of proteintyrosine kinases, is known to play an important early role in TCR-mediated signal transduction. Cross-linking of TCR leads to the rapid activation of p56 lck , which in turn phosphorylates and activates the protein-tyrosine kinase ZAP70. Activation of p56 lck and ZAP70 is required for the subsequent activation of the calcium-, PKC-, and Ras-dependent signaling cascades that regulate T cell activation. To determine directly if p56 lck is important in TCR-mediated phosphorylation of CREB on Ser 133 , we compared the effects of TCR cross-linking on CREB phosphorylation in wild-type Jurkat T cells and in the JCAM-1
FIG. 3. Effects of protein kinase inhibitors on ␣-CD3-induced phosphorylation of CREB in thymocytes.
Freshly isolated murine thymocytes were preincubated with medium alone (␣-CD3, forskolin, or ionomycin) or the indicated protein kinase inhibitors at 37°C for 30 min. The cells were then activated by treatment with immobilized ␣-CD3 mAb or forskolin (A), immobilized ␣-CD3 mAb (B), or ionomycin (C). Ser 133 phospho-CREB was detected by Western blot analysis as described in the legend to Fig. 1 . In all experiments, total levels of CREB protein in each sample were shown to be equivalent by Western blot analysis with an ␣-CREB antibody (data not shown). Uns, unstimulated.
FIG. 4. Requirement for p56 lck in TCR-induced phosphorylation of CREB in Jurkat T cells. Jurkat T cells (A-C), JCAM-1 p56
lck -deficient T cells (B and C), or JCAM-1/p409 lck cells stably transfected with a p56 lck expression vector (B) were activated by treatment with PMA, ionomycin, or PMA ϩ ionomycin (A and C) or immobilized OKT3 (B) for the times shown (in minutes). Ser 133 phospho-CREB (␣-pCREB) and total CREB protein (␣-CREB) were detected by Western blot analysis as described in the legend to Fig. 1 . Uns, unstimulated.
mutant of Jurkat cells that lacks p56
lck (Fig. 4B) . As shown in Fig. 4B , cross-linking of TCR on JCAM-1 cells failed to induce detectable CREB phosphorylation. This was not due to a deficiency in CREB protein because JCAM-1 and wild-type Jurkat cells contained comparable levels of CREB protein as assessed by Western blot analysis with an ␣-CREB antibody (Fig. 4B) . More important, treatment of the p56 lck -deficient JCAM-1 cells with PMA induced CREB phosphorylation that was indistinguishable from that seen in wild-type Jurkat cells (Fig. 4C) (38, 39) . Activated MAPKs as well as members of the pp90 rsk family are known to translocate to the nucleus and to phosphorylate several transcription factors (39, 40) . In PC12 cells, a Ras-dependent Ser/Thr protein kinase has been shown to phosphorylate CREB in response to nerve growth factor stimulation (11) . Subsequent analyses showed this CREB kinase to be identical to the Ser/Thr protein kinase RSK2 (41) . The p21 ras pathway is known to be rapidly activated in response to TCR engagement by both PKC-dependent and protein-tyrosine kinase-dependent pathways (42, 43) , thus raising the possibility that Ras and RSK2 might be important for CREB phosphorylation in response to TCR engagement. To more directly determine the role of p21 ras in TCR-induced CREB phosphorylation, we cotransfected Jurkat T cells with an expression vector encoding a recombinant form of CREB (Gal4-CREB) and expression vectors encoding either a constitutively active Ras (CA-Ras) or a dominant-negative mutant Ras protein, N17Ras (DN-Ras). The difference in the size of Gal4-CREB and endogenous CREB made it possible to distinguish the two molecules by SDSpolyacrylamide gel electrophoresis. Co-transfection with CARas and Gal4-CREB resulted in CREB phosphorylation, even in the absence of TCR engagement (Fig. 5A) . More important, expression of DN-Ras markedly inhibited ␣-CD3-induced phosphorylation of Gal4-CREB (Fig. 5A) . Moreover, ␣-CD3 (but not CA-Ras)-induced CREB phosphorylation was inhibited by the PKC inhibitor bisindolylmaleimide I, suggesting that Ras lies downstream of PKC in the CREB activation pathway in T cells (Fig. 5A) . These results were not due simply to differences in transfection efficiencies or to levels of expression of Gal4-CREB in the different transfected cell cultures because identical results were observed in at least three independent transfection experiments.
Activated Ras is known to activate Raf-1, MEK, and MAPK in T cells. To assess the role of Raf-1 in TCR-mediated CREB phosphorylation, we co-transfected Jurkat T cells with Gal4-CREB and a vector encoding a dominant-negative form of Raf-1 (Fig. 5B) . Overexpression of the dominant-negative Raf-1 form inhibited ␣-CD3-mediated CREB phosphorylation. This result was not due to differences in transfection efficiencies or levels of expression of the Gal4-CREB protein because an aliquot of the same culture of doubly transfected cells (Gal4-CREB ϩ dominant-negative Raf-1) stimulated with forskolin demonstrated significant Gal4-CREB phosphorylation (Fig. 5B) . To assess the role of MEK/MAPK in CREB phosphorylation following TCR cross-linking, we tested the effects of the MEK inhibitor PD98059 on CREB phosphorylation in normal T cells following activation with either ␣-CD3 or forskolin. As shown in Fig. 6 , PD98059 inhibited CREB Ser 133 phosphorylation in response to TCR cross-linking, but had no effect on forskolininduced CREB phosphorylation. Taken together, these results were consistent with a model in which activation of Ras, Raf-1, and MEK is required for TCR-mediated CREB phosphorylation.
Role of RSK2 in TCR-mediated CREB Phosphorylation-As described above, in PC12 cells, nerve growth factor-mediated activation of Ras leads to the subsequent activation of RSK2, which in turn phosphorylates and activates CREB. To assess the role of RSK2 in the TCR-induced phosphorylation of CREB, we transfected Jurkat T cells with expression vectors encoding wild-type RSK2 or a catalytically inactive mutant of RSK2 (RSK2(KR100)) along with a Gal4-CREB expression vector. TCR-mediated stimulation of Jurkat T cells transfected with Gal4-CREB resulted in low level phosphorylation of Gal4-CREB (Fig. 7A, eighth lane) . Phosphorylation of Gal4-CREB was dramatically increased by co-transfection of the wild-type RSK2 expression vector (Fig. 7A, twelfth lane) . This increase in Gal4-CREB phosphorylation required a kinase-active form of RSK2 because it was not observed in cells co-transfected with catalytically inactive RSK2(KR100) (Fig. 7A, fourteenth lane) . These differences in Gal4-CREB phosphorylation were not due to differences in transfection efficiencies or levels of expression in the presence or absence of bisindolylmaleimide I (Bis) was detected by Western blot analysis as described in the legend to Fig. 1 . B, Jurkat T cells were transiently transfected with expression vectors encoding Gal4-CREB and a dominant-negative form of Raf-1 (DN-raf) as indicated. Following transfection, the cultures were divided into two aliquots. One aliquot was activated with immobilized ␣-CD3 mAb, whereas the other was treated with forskolin. Phosphorylation of Gal4-CREB Ser 133 (pGal4-CREB) was detected by Western blot analysis as described in the legend to Fig. 1 . Uns, unstimulated.
of Gal4-CREB because treatment of an aliquot of each transfected culture with forskolin induced comparable levels of Gal4-CREB phosphorylation, whether or not the cells were co-transfected with the RSK2 expression vector (Fig. 7A, compare  ninth, twelfth, and fifteenth lanes) . Thus, the effects of RSK2 overexpression on CREB phosphorylation were specific for TCR-mediated activation. In addition, the RSK2-dependent phosphorylation of CREB in response to ␣-CD3 stimulation required activation of PKC because bisindolylmaleimide I, but not H-8, inhibited Gal4-CREB phosphorylation in cells cotransfected with the RSK2 expression vector and stimulated by TCR engagement (Fig. 7B) . Taken together, these experiments demonstrated that RSK2 participates in the TCR-mediated phosphorylation of CREB and suggested that RSK2 and PKC may belong to a common signaling pathway. Finally, TCRmediated Gal4-CREB phosphorylation in Jurkat cells transfected with RSK2 was abrogated by co-transfection with a dominant-negative Ras expression vector (Fig. 7C) , confirming the requirement for Ras in RSK2-dependent, ␣-CD3-induced CREB Ser 133 phosphorylation.
DISCUSSION
Activation of pre-existing CREB by phosphorylation on Ser 133 is one of the early events in the signaling pathways activated by engagement of the T cell antigen receptor. This rapid and transient activation of CREB is critically important for the normal transcriptional induction of specific AP1 family members, the transcriptional activation of the IL-2 gene, and subsequent cell cycle progression and T cell proliferation (12) . In the studies described in this report, we have investigated the signaling pathways responsible for CREB phosphorylation in normal peripheral T cells and thymocytes. Our results demonstrate that CREB phosphorylation in these cells can be mediated by at least three distinct pathways: (i) a PKA-dependent pathway that can be simulated by treatment with forskolin and blocked by H-8, (ii) a calcium/calmodulin-dependent pathway that can be simulated by treatment with ionomycin and blocked by W-7, and (iii) a PKC-dependent pathway that can be simulated by treatment with PMA and blocked by chelerythrine chloride, H-7, and bisindolylmaleimide I. Despite the multiplicity of signaling pathways that are capable of mediating CREB phosphorylation in T cells, our experiments are consistent with a model in which CREB phosphorylation and activation are mediated by a single signaling pathway that requires activation of p56 lck , PKC, Ras, Raf-1, MEK, and RSK2. Our conclusion that activation of PKC is required for TCRmediated CREB Ser 133 phosphorylation is based on the use of pharmacological inhibitors that could potentially have effects on multiple signal transduction molecules. However, the validity of our conclusions concerning the role of PKC is supported by the following considerations: (i) three different inhibitors of PKC abrogated TCR-mediated CREB phosphorylation, whereas three inhibitors of PKA and calcium/calmodulin kinase pathways had no effect on CREB phosphorylation following TCR crosslinking; (ii) in parallel control experiments, PKC inhibitors had no effect on forskolin-or ionomycin-mediated CREB phosphorylation in the same cells; and (iii) our results in normal T cells and thymocytes are consistent with a previous report that demonstrated that depletion of activated PKC by prolonged treatment of Jurkat T cells with PMA also abrogated TCRmediated CREB Ser 133 phosphorylation (7) . Moreover, the previous finding of the importance of PKC in mediating CREB phosphorylation following immunoglobulin cross-linking in B cells suggests that common signaling pathway(s) may regulate CREB activation in response to antigen receptor cross-linking in these two different lymphoid cell lineages (15) .
Previous studies have demonstrated a critical role for p21 (pGal4-CREB) was detected by Western blot analysis as described in the legend to Fig. 1 . Uns, unstimulated.
Raf-1, and MEK also play critical roles in the TCR-mediated activation of CREB in T cells. Specifically, we have shown that (i) expression of constitutively active Ras resulted in the phosphorylation of CREB even in the absence of TCR signaling; (ii) TCR-induced phosphorylation of CREB was inhibited by expression of dominant-negative mutant Ras or Raf-1 proteins as well as by PD98059, an inhibitor of MEK; and (iii) expression of the dominant-negative Ras protein also abrogated the RSK2-dependent phosphorylation of CREB following TCR engagement. Although our findings do not allow us to definitively conclude whether Ras lies upstream or downstream of RSK2 in the CREB activation pathway, by analogy with the PC12 system (11, 41) , we would propose a model in which TCR engagement leads to the activation of Ras, Raf-1, and MEK, which in turn results in RSK2 activation.
At least two signaling pathways have been shown to be capable of activating p21 ras in response to TCR engagement (26 -31, 44) . The first of these requires protein-tyrosine kinases and can be blocked by inhibitors such as herbimycin. The second pathway appears to be unique to T cells and involves the activation p21
ras by PKC. Our findings that PKC inhibitors block TCR-mediated CREB phosphorylation but fail to block CREB phosphorylation in response to expression of constitutively active p21 ras and that expression of dominant-negative N17Ras also blocks TCR-mediated CREB phosphorylation suggest that PKC-mediated activation of p21 ras is important for TCR-mediated activation of CREB.
When considered in the context of our current understanding of TCR-mediated signaling pathways, our results suggest the following working model for TCR-mediated CREB activation. Cross-linking of TCR leads to the rapid activation of p56 lck , which results in the activation of PKC. Activated PKC in turn leads to the activation of Ras-Raf-1-MEK-MAPK. Activated MAPK then activates RSK2, which phosphorylates CREB on Ser 133 . It should be emphasized that such a straightforward linear signaling model is likely oversimplified and that several features of the model remain untested or unproved. For example, the pathways by which activated p56 lck leads to PKC activation remain unclear, as do the links between PKC and Ras. Similarly, we have not formally demonstrated the relationship between activated MAPK and RSK2 activation in T cells, nor have we demonstrated that RSK2 directly phosphorylates CREB Ser 133 in vivo. Despite these caveats, our results have identified a number of the critical signaling components that regulate CREB activation following stimulation through the T cell antigen receptor, and our working model suggests future experiments designed to more precisely elucidate this important T cell signaling pathway.
The inhibition of T cell activation is important for the treatment of both autoimmune diseases and transplant rejection. Currently available immunosuppressive agents target the calcineurin-dependent activation of NFAT (e.g. cyclosporin A) or the pathway that leads to the activation of NF-B (e.g. glucocorticoids and aspirin). Given the importance of CREB phosphorylation in T cell activation, the CREB activation pathway described herein represents a potentially novel target for the development of immunosuppressive drugs. To obtain specificity, it will likely be important to inhibit distal parts of the pathway that are specific for CREB phosphorylation rather than proximal signaling molecules such as PKC or Ras, which play more generalized roles in cellular homeostasis in many mammalian cell lineages. Nevertheless, our previous finding that expression of a dominant-negative (unphosphorylatable) form of CREB markedly inhibits IL-2 expression and T cell proliferation (12) suggests that specific inhibitors of this pathway may have potent immunosuppressive effects.
